Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction

  • PDF / 857,659 Bytes
  • 8 Pages / 595.276 x 790.866 pts Page_size
  • 33 Downloads / 193 Views

DOWNLOAD

REPORT

ORIGINAL ARTICLE

Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction Tomoko Morita‑Ogawa1   · Hiroki Sugita1 · Hironobu Minami2 · Takuhiro Yamaguchi3 · Kazuhiko Hanada1 Received: 2 May 2020 / Accepted: 8 September 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract Purpose  The pharmacokinetics (PKs) of cisplatin have not been investigated in patients with renal dysfunction, characterized by creatinine clearance (Ccr) 

Data Loading...

Recommend Documents
Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement Therapy

172 48 154KB

Long-term renal outcomes after elective percutaneous coronary intervention in patients with advanced renal dysfunction

175 94 876KB

Renal toxicity reports with zoledronic acid

166 33 120KB

Renal Cancer

163 64 6MB

Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function

166 105 657KB

Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-peme

152 51 545KB

COVID-19 and financial toxicity in patients with renal cell carcinoma

134 13 733KB

Renal Cancer Contemporary Management

182 17 22MB

Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease

139 5 683KB

Clinical Implications of Renal Cancer

150 95 20MB

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

158 116 2MB

Correction to: The Association Between Renal Tubular Dysfunction and Zinc Level in a Chinese Population Environmentally

148 89 104KB